NCT03782818View on ClinicalTrials.gov

Olaparib for PAH: a Multicenter Clinical Trial

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Olaparib

Olaparib up to 300 mg BID for 24 weeks

Trial Locations (3)

T6G 2B7

University of Alberta Hospital, Edmonton

M5G 2C4

UHN-Toronto General Hospital, Toronto

G1V4G5

IUCPQ-UL, Québec

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

AstraZeneca

INDUSTRY

lead

Laval University

OTHER